This article summarized the latest R&D progress of Nemolizumab, the Mechanism of Action for Nemolizumab, and the drug target R&D trends for Nemolizumab.
This article summarized the latest R&D progress of Mycophenolate Sodium, the mechanism of action for Mycophenolate Sodium, and the drug target R&D trends for Mycophenolate Sodium.
TLRs are innate immune receptors that are responsible, directly or indirectly, for detecting pathogen-associated molecular patterns (PAMPs) and responding to them through the activation of innate and adaptive immune pathways.
Molecular Templates has commenced dosing in Phase 1 trial of MT-8421, a unique engineered toxin body targeting CTLA-4, for treating advanced solid tumors.
This article summarized the latest R&D progress of Naftifine Hydrochloride, the Mechanism of Action for Naftifine Hydrochloride, and the drug target R&D trends for Naftifine Hydrochloride.
TTerns Pharmaceuticals reported the initial participant administration in Phase 1 Clinical Testing of TERN-601 Oral GLP-1 Receptor Agonist, a potential treatment for obesity.
This article summarized the latest R&D progress of Naloxegol Oxalate, the Mechanism of Action for Naloxegol Oxalate, and the drug target R&D trends for Naloxegol Oxalate.
Endothelin receptor are G protein-coupled receptors (GPCRs) of the β-group of rhodopsin receptors that bind to endothelin ligands, which are 21 amino acid long peptides derived from longer prepro-endothelin precursors.
Clinical-stage biopharmaceutical firm Inhibrx declared initial Phase 1 trial results for INBRX-109, used with Irinotecan and Temozolomide, to treat advanced, non-removable Ewing sarcoma. The trial focused on efficacy and safety.
Motifs in biology refer to nucleotide or amino-acid sequence patterns that are prevalent and usually associated with the biological function of a macromolecule.